Small molecule high throughput screen using AstraZeneca facilities
Small molecule high throughput screen using AstraZeneca facilities is a funding call from UKRI – Medical Research Council (MRC) that closes 28 January 2027. Funding: £270,000. Eligibility: Open to UK research organisations eligible for UKRI funding (universities, approved institutes); the project lead must direct the work.
- Funder
- UKRI – Medical Research Council (MRC)
- Deadline
- 28 Jan 2027 (105 days)
- Amount
- £270,000
- Region / eligibility
- United Kingdom
- Career stage
- established / PI
- Fields
- chemistry, pharma process
- Reference
- —
- Official call
- UKRI listing
Eligibility in plain language
Open to UK research organisations eligible for UKRI funding (universities, approved institutes); the project lead must direct the work.
Who should apply
Synthetic, physical and analytical chemists, medicinal chemists and pharma process / drug-development teams — best fit for PIs and research groups.
Summary from source
Apply for funding to run a high throughput screen (HTS) using AstraZeneca’s compound library and screening robots. There are two funding opportunities per year that are open to all targets. MRC
Raw eligibility text
This opportunity is open to organisations with standard eligibility. Check if your organisation is eligible . Who is eligible to apply To be eligible to apply for this funding opportunity you must show that you will direct the project and be actively engaged in the work. For applicants who do not have a contract of employment for the duration of the proposed project, by submitting an application the research organisation is confirming, if it is successful: contracts will be extended beyond the end date of the project all necessary support for the project and the applicants will be provided, including mentorship and career development for early career researchers Demand management You can only submit one application as project lead to this funding opportunity. Resubmissions We will not accept uninvited resubmission of applications that were submitted after 1 April 2026 to Medical Research Council (MRC), the rest of UK Research and Innovation (UKRI) or any other funder. An uninvited resubmission is an application that was previously unsuccessful and has been submitted again without being invited by MRC. This includes applications that are unchanged, minimally revised, or substantially the same as the original submission. Uninvited resubmissions will be rejected. You should contact us if you are unsure whether your application is a resubmission. Find contacts in the ‘contact details’ section. Who is not eligible to apply Research applications that are led by commercial entities